Quick Answer
Larimar Therapeutics, Inc. reported Stockholders Equity of $78.09 million for the year ending 2025.
- Larimar Therapeutics, Inc. showed a decrease of -54.6% in Stockholders Equity from 2024 to 2025.
- This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: $125.42 million | Q3 2014: $111.20 million | Q1 2015: $221.67 million | Q2 2015: $206.19 million | Q3 2015: $189.70 million | Q1 2016: $154.43 million | Q2 2016: $142.24 million | Q3 2016: $130.17 million | Q1 2017: $110.77 million | Q2 2017: $99.63 million | Q3 2017: $89.23 million | Q1 2018: $65.00 million | Q2 2018: $52.02 million | Q3 2018: $103.94 million | Q1 2019: $1.22 million | Q2 2019: $543.0 thousand | Q3 2019: $1.90 million | Q1 2020: $2.26 million | Q2 2020: $112.54 million | Q3 2020: $102.64 million | Q1 2021: $78.78 million | Q2 2021: $67.53 million | Q3 2021: $72.07 million | Q1 2022: $57.11 million | Q2 2022: $50.06 million | Q3 2022: $118.66 million | Q1 2023: $106.24 million | Q2 2023: $99.93 million | Q3 2023: $92.71 million | Q1 2024: $230.84 million | Q2 2024: $211.40 million | Q3 2024: $198.40 million | Q1 2025: $144.27 million | Q2 2025: $119.85 million | Q3 2025: $139.04 million.
- Over the full 15 years of available data (2011 to 2025), Larimar Therapeutics, Inc.'s Stockholders Equity has grown by 290.8%.
- Historical annual values: Fiscal year 2025: $78.09 million | Fiscal year 2024: $171.81 million | Fiscal year 2023: $81.72 million | Fiscal year 2022: $110.90 million | Fiscal year 2021: $64.41 million | Fiscal year 2020: $89.69 million | Fiscal year 2019: -$694.0 thousand | Fiscal year 2018: $2.91 million | Fiscal year 2017: $78.22 million | Fiscal year 2016: $121.73 million | Fiscal year 2015: $169.11 million | Fiscal year 2014: $104.44 million | Fiscal year 2013: -$68.57 million | Fiscal year 2012: -$54.73 million | Fiscal year 2011: -$40.92 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: